Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 3759)

(1) CHANGE IN ACCOUNTING POLICIES; AND (2) CHANGE OF AUTHORISED REPRESENTATIVE

The board of directors (the "**Board**") of Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that the Board has resolved and approved, among others: (i) the proposed changes in the Company's accounting policies (the "**Changes in Accounting Policies**"); and (ii) the change of an authorised representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

1. CHANGES IN ACCOUNTING POLICIES

This announcement is made pursuant to the requirements of Rule 13.09(2) of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571).

The audit committee of the Board (the "**Audit Committee**") and the Board reviewed and approved the Changes in Accounting Policies, on August 10, 2026 and August 20, 2026, respectively. Details of the Changes in Accounting Policies are as follows:

I. Overview of Changes in Accounting Policies

(i) Nature, reasons and effective date of the Changes in Accounting Policies

The Company is a leading fully-integrated pharmaceutical R&D services platform with global operations, providing an integrated research, development and manufacturing service system covering the full cycle of drug discovery, preclinical and clinical development for multiple therapeutic modalities, including small molecule, biologics and cell and gene therapy products. In recent years, the proportion of new drug modalities and cross-modality drugs, including oligonucleotides, peptides and bioconjugates, in both global and China's innovative drug R&D pipelines has increased significantly, becoming an important driver of industry growth. In order to better align with this development trend, the Company will fully leverage the comprehensive advantages of its "*end-to-end, fully-integrated and multiple modalities capable*" service platform to promote efficient synergy across business lines and improve project R&D and delivery efficiency, so as to more effectively meet customer needs. Accordingly, the Company has reorganized its original service platforms into three major platforms, namely, laboratory services, CDMO services and clinical development services.

The Changes in Accounting Policies are made in accordance with the relevant requirements of Accounting Standards for Business Enterprises No. 35 – Segment Reporting and Interpretation No. 3 of the Accounting Standards for Business Enterprises, and based on the Company's business development and internal management needs. The Changes in Accounting Policies constitute a voluntary change in accounting policies and are applicable from the second quarter of 2026.

(ii) Accounting policies adopted prior to the Changes in Accounting Policies

Prior to the Changes in Accounting Policies, the Company's reportable segments mainly comprised: laboratory services, CMC (small molecule CDMO) services (chemistry and formulation process development and manufacturing services), clinical development services, biologics and cell and gene therapy services, and other segments.

(iii) Accounting policies adopted after the Changes in Accounting Policies

After the Changes in Accounting Policies, the Company's reportable segments mainly comprise: laboratory services, CDMO services, clinical development services and other segments. The principal service offerings of each segment are as follows:

(1) Laboratory services: includes laboratory chemistry and bioscience services, covering the synthesis and preparation, *in vitro* biology, *in vivo* pharmacology, DMPK and safety assessment for innovative drug projects across diverse molecular modalities, including small molecule drugs, biologics, oligonucleotides, peptides, antibodies, bioconjugates (ADC and XDC) and CGT products, etc.;

(2) CDMO services: includes API process development and manufacturing, materials science/pre-formulation, formulation development and manufacturing, and analytical development services, covering a broad range of products including small molecules, biologics, oligonucleotides, peptides, bioconjugates (including ADC and XDC), and gene therapy products;

(3) Clinical development services: includes overseas clinical development services (including radiolabeled science services and early-stage clinical trial services) and domestic clinical development services (including clinical research services and site management services); and

(4) Other segments: includes non-core businesses, sales of raw materials and scrap, and other income.

II. Impacts of Changes in Accounting Policies on the Company

The Changes in Accounting Policies only affect the presentation of segment information in the notes to the financial statements, and do not affect the Company's revenue, net profit, net assets or other financial statement figures. In accordance with the requirements of the Accounting Standards for Business Enterprises, the Company will prepare the segment information in its 2026 interim report on the basis of the adjusted reportable segments commencing from the second quarter of 2026, and will re-present the comparative figures for 2025 accordingly. The revised presentation of reportable segments is more consistent with the Company's current business development trends and will better assist investors in understanding and analysing the Company's operations.

The Changes in Accounting Policies do not involve retroactive adjustment of revenue, net profit, net assets or other financial statement figures for previous years, will have no material effect on the Company's financial position, operating results or cash flows, and do not prejudice the interests of the Company and all of its shareholders. The Changes in Accounting Policies will not have any impact on the Company's audited consolidated financial statements prepared in accordance with IFRS Accounting Standards (which include all International Financial Reporting Standards, International Accounting Standards and Interpretations) as issued by the International Accounting Standards Board. In the Company's subsequent annual reports and interim reports, the business segment financial data for the corresponding reporting period will be presented under the adjusted reportable segments, and the comparative business segment financial data for the corresponding prior reporting period will be restated and re-presented on the same basis.

III. Opinion of the Audit Committee of the Board

The Audit Committee is of the opinion that the Changes in Accounting Policies are made in compliance with the relevant requirements of Accounting Standards for Business Enterprises No. 35 – Segment Reporting and Interpretation No. 3 of the Accounting Standards for Business Enterprises, and based on the Company's business development and internal management needs, and constitute a reasonable voluntary change in accounting policies. The Changes in Accounting Policies do not involve retroactive adjustment of financial data such as annual revenue, net profit, net assets or other financial data for previous years and do not prejudice the interests of the Company and all of its shareholders. The Audit Committee unanimously approved the Changes in Accounting Policies.

In accordance with the Rules Governing the Listing of Stocks on the ChiNext Board of the Shenzhen Stock Exchange and other applicable laws, regulations and departmental rules, the Changes in Accounting Policies are not required to be submitted to the shareholders' general meeting for approval.

2. CHANGE OF AUTHORISED REPRESENTATIVE

The Board hereby announces that Mr. LOU Xiaoqiang ("**Mr. LOU**"), a director of the Company, has ceased to act as an authorised representative of the Company under Rule 3.05 of the Listing Rules with effect from August 20, 2026 due to an adjustment in his work duties. With effect from the same date, the Board has resolved to approve the appointment of Mr. LI Shing Chung Gilbert ("**Mr. LI**"), a director of the Company, as the authorised representative of the Company in place of Mr. LOU.

Upon ceasing to be an authorised representative, Mr. LOU will continue to serve as the chief operating officer, president and an executive director of the Company and there is no other change to his roles and responsibilities. Mr. LOU has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation as an authorised representative that needs to be brought to the attention of the Stock Exchange or the shareholders of the Company.

The Board would like to take this opportunity to express its gratitude to Mr. LOU for his contribution as an authorised representative and to welcome Mr. LI on his new appointment.

Ms. Mak Po Man Cherie, the company secretary of the Company, will continue acting as the Company's authorised representative.

GENERAL

The Board considers that the Changes in Accounting Policies and the change of authorised representative are in the interests of the Company and its shareholders as a whole.

By order of the Board
Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
August 20, 2026

As at the date of this announcement, the Board of Directors comprises Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei as executive Directors; Mr. LI Shing Chung Gilbert as employee representative Director; Ms. WAN Xuan as non-executive Director; Ms. LI Lihua, Prof. TSANG King Fung and Ms. SHEN Rong as independent non-executive Directors.